Skip to main content

Table 6 Data from sleep questionnaires including domain scores

From: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study

  PEA Placebo
Baseline Week 4 Week 8 Baseline Week 4 Week 8
Epworth Sleepiness Scale 6.5 ± 4.4 4.6 ± 3.8 4.7 ± 4.1 6.7 ± 4.1 4.8 ± 3.9 4.3 ± 4.1
PROMIS 61.5 ± 6.0 56.8 ± 6.5 55.3 ± 6.6 62.2 ± 6.5 56.5 ± 6.7 55.1 ± 9.0
SIQ Total score 45.1 ± 15.7 36.9 ± 13.1 37.1 ± 12.4 45.0 ± 12.4 37.1 ± 15.0 36.8 ± 15.1
SIQ Physiological 15.8 ± 6.0 12.2 ± 4.5 12.4 ± 4.7 16.2 ± 4.9 12.8 ± 5.7 12.6 ± 5.5
SIQ Responses to Sleep Inertia 13.8 ± 5.2 12.3 ± 4.9 11.6 ± 4.3 14.5 ± 4.6 12.0 ± 4.7 12.0 ± 5.0
SIQ Cognitive 10.5 ± 4.6 9.0 ± 3.7 8.0 ± 3.2a 9.4 ± 3.0 7.4 ± 3.6 7.8 ± 4.1
SIQ Emotional 4.9 ± 2.6 4.4 ± 2.3 4.2 ± 1.6 4.9 ± 2.3 4.5 ± 2.7 4.8 ± 2.8
SIQ Time to feel completely awake 25.9 ± 25.3 18.4 ± 21.1 14.7 ± 17.5a 23.6 ± 23.8 20.4 ± 20.4 22.4 ± 25.1
  1. N.B. Data presented as mean ± standard deviation;  asignificant difference between groups at p < 0.05; PEA  Palmitoylethanolamide, PROMIS Patient Reported Outcomes Measurement Information System, SIQ The Sleep Inertia Questionnaire